Pharmacy Times®
Specialty Pharmacy Times
  • Keeping an Eye on Hepatitis C Virus Drug Approvals
  • Community Specialty Pharmacy: The Time Is Now!
  • Specialty Pipeline Highlights
  • Evaluating and Elevating Specialty Pharmacists Through Certification
  • How Will Specialty Pharmacy Be Affected By Cost Containment?
  • Psoriatric Arthritis: An Overview
Despite First Confirmed Case, Ebola Poses No Threat to United States
Davy James, Associate Editor
Officials stress that the strength of the US health care system will contain the virus.
Uric Acid Correlated with Disease Activity in Multiple Sclerosis
Michael R. Page, PharmD, RPh
A metaanalysis shows that levels of an antioxidative endogenous metabolic byproduct—uric acid—are correlated with disease activity in multiple sclerosis.
Ebola Epidemic Deemed the Most Severe Public Health Emergency of Modern Times
Davy James, Associate Editor
As the Ebola outbreak worsens, interest in therapies using recovered victims’ blood grows.
Opsumit by Actelion Pharmaceuticals US, Inc
Michael R. Page, PharmD, RPh
Opsumit (macitentan) was approved to reduce the risk of hospitalization and delay disease progression in patients with WHO group I pulmonary arterial hypertension.
Zydelig by Gilead Sciences, Inc
Michael R. Page, PharmD, RPh
The FDA has approved Zydelig (idelalisib) tablets for the later-line treatment of 3 types of cancer, including chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.
Featured Video
The Challenges of a Mid-Sized Specialty Pharmacy
Michael Nameth, RPh, MBA, chief executive officer of Aureus Health Services, discusses the major hurdles facing mid-size specialty pharmacies.
Industry Guide
We've created this Industry Guide with close to 300 companies and organizations as a one-stop guide for industry stakeholders in the specialty pharmacy space.
Current Issue
Volume: 5
Number: 4
Conference Calendar
â—„        October 2014        â–ş
Featured Company Profile
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.